A real‑world study of 888 solid‑tumor patients published in Nature Medicine found routine paired tumor‑normal whole‑genome sequencing (WGS) delivered actionable results with clinical consequences in 41% of cases. WGS succeeded in 89% of tests with a median turnaround of six working days and identified potentially actionable biomarkers in 73% of patients. The paper reports biomarker‑informed therapies were started in a substantial subset and were associated with longer median overall survival. The findings supply empirical support for broader WGS adoption in comprehensive cancer centers and for integrating tumor‑agnostic genomic testing into routine care pathways.